Lys Therapeutics
Created in 2021
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
3,042Activities
Technologies
Entity types
Location
56 Rue Saint-Jean-de-Dieu, 69007 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 12
SIREN
895069904Engaged corporates
20
5 14Added in Motherbase
1 year, 7 months ago
biotech Value proposition
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation.
In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson's disease, the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) overexpressed in these patients leads to the degradation of tight junctions and BBB dysfunction, allowing the transmigration of inflammatory cells and toxic molecules into the brain parenchyma, triggering excitotoxicity and neuroinflammation, major contributors to neurodegeneration.
Lys Therapeutics' lead drug candidate, LYS241, is a first-in-class monoclonal antibody with a unique mechanism of action that effectively counteracts these pathological mechanisms. Specifically, LYS241 acts in blood vessels to prevent the binding of tPA to NMDAr without interfering with the physiological function of NMDAr. By inhibiting this interaction, NMDAr can function normally, and the activation of deleterious downstream cellular pathways is stopped. Tight junctions are restored, endothelial cells return to their healthy state, and BBB function is restored, protecting the brain from neuroinflammatory and neurodegenerative cascades.
Lys Therapeutics' approach to targeting neuroinflammation to combat neurodegeneration represents a promising pathway in the quest for effective treatments for these debilitating disorders.
Stroke, Multiple Sclerosis, Neurology, Neurodegenerative disorders, Healthcare, Biotechnology, Pharma, Drug development, Antibody, Parkinson, Parkinson's Disease, and Neurovascular diseasesOriginal language
First-in-class biotherapies against neurological diseases.
Targeting neuroinflammation to tackle neurodegeneration.
Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation.
In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson's disease, the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) overexpressed in these patients leads to the degradation of tight junctions and BBB dysfunction, allowing the transmigration of inflammatory cells and toxic molecules into the brain parenchyma, triggering excitotoxicity and neuroinflammation, major contributors to neurodegeneration.
Lys Therapeutics' lead drug candidate, LYS241, is a first-in-class monoclonal antibody with a unique mechanism of action that effectively counteracts these pathological mechanisms. Specifically, LYS241 acts in blood vessels to prevent the binding of tPA to NMDAr without interfering with the physiological function of NMDAr. By inhibiting this interaction, NMDAr can function normally, and the activation of deleterious downstream cellular pathways is stopped. Tight junctions are restored, endothelial cells return to their healthy state, and BBB function is restored, protecting the brain from neuroinflammatory and neurodegenerative cascades.
Lys Therapeutics' approach to targeting neuroinflammation to combat neurodegeneration represents a promising pathway in the quest for effective treatments for these debilitating disorders.
Home - Lys Therapeutics
Lys Therapeutics, first-in-class biotherapies against neurological diseases
https://lystherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Région Normandie National and local authorities, Government Administration | Région Normandie National and local authorities, Government Administration | Other 25 Oct 2024 | | |
 Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Other 25 Oct 2024 | | |
 Normandie Incubation Professional Training & Coaching | Normandie Incubation Professional Training & Coaching | Other 28 Sep 2024 | | |
 | Ministère de la Santé | Other 25 Sep 2024 | | |
 | Gouvernement | Other 25 Sep 2024 | | |
 Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 25 Sep 2024 | | |
 Ministry of Economy Government Administration | Ministry of Economy Government Administration | Other 25 Sep 2024 | | |
 Biogen Biotechnology, Biotechnology Research | Biogen Biotechnology, Biotechnology Research | Other 22 Mar 2024 | | |
 La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | La French Tech Saint-Etienne Lyon French Tech, IT Services and IT Consulting | Other 13 Mar 2024 | | |
 PULSALYS Research, Research Services | PULSALYS Research, Research Services | Other 23 Sep 2024 | | |